is an attorney with Banner & Witcoff, Ltd. Dr. Wu focuses her practice on patent prosecution and patent portfolio development in the fields of biotechnology, molecular diagnostics, medical devices and pharmaceuticals. She has extensive experience in preparation and prosecution of U.S. and foreign patent applications relating to genes, proteins, enzymes, recombinant antibodies, microorganisms, medical diagnostics, blood products, cell matrices, tissue engineering, dietary and food supplements, cancer treatments, gene therapy, drug discovery and formulation, epigenetics, biopolymer, vaccine, and genomics.
For more information or to contact Dr. Wu, please visit her Firm Profile Page.
A well-devised intellectual property (IP) portfolio can go a long way to ensure a startup biotech company’s business success in the marketplace. Patents allow a patent holder to exclude others from making, using, offering to sell, selling or importing a similar product based on what is claimed in the patent while the patent is in force (35 U.S.C. 154). Biotech startups generally invest in utility patents to protect core inventions and serve as barriers to entry against competitors. When faced with budget constraints, biotech startups can tap into less expensive IP protection options to boost market position, drive up value, attract venture capital funds and generate revenue, including cross-licensing and/or settlement agreements.